CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 19787/S005

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW	1. ORGANIZ	ATION	2. NDA Number
	HFD - 1	10	19-787
3. Name and Address of Pfizer, Inc. 235 East 42nd Stree New York, NY 10017-	4. Supplement(s) Number(s) S-005 (SCM) Date(s) 10-25-94		
5. Drug Name	6. Nonproprietary Name		8. Amendments & Other (reports,
NORVASC	Amlodip	ine Besylate	etc) - Dates
7. Supplement Provides For: Requesting the approval of as an additional alternate package site for Norvasc Tablets.			
9. Pharmacological Category 10. How Dispensed			d 11. Related IND(s)/
Antihypertensive and $\frac{\sqrt{x}}{RX}$ PX $\frac{}{}$ OTC Antianginal			NDA(s)/DMF(s)
12. Dosage Form(s) Tablet			
14. Chemical Name and 3-Ethyl-5-methyl-2 chlorophenyl)-1,4- pyridinedicarboxyl	15. Records/Reports Current		
	~c 1	\$0 ₅ H	/x/ Yes /_/ No
Hacosc	CO2CH2CH2		Reviewed
N 3 C N	/x/ Yes /// No		
16. Comments: The applicant requested for approval of as an additional alternate package site for Norvasc Tablets. An autorization letter to refer to DMF was provided. An EER request was submitted on 01/27/95. After receiving the reply from compliances, the applicant will be informed accordingly.			
17. Conclusions and Recommendations: An EER request was submitted on 1/27/95. Reply was received on 2/5/95 and as of 2/2/95 the status is acceptable. Approval letter is being sent to the applicant.			
18. REVIEWER			
Name Ramsharan D. Mittal	Signature	/S/ <u></u>	Date Completed 02/07/95
19. Distribution: /// Original Jacket // Reviewer // Division File // CSO			
y 181 -217195			